BIM

114.2

-1.13%↓

SRT3

228.6

+0.13%↑

GXI

56.7

+2.53%↑

ICAD

20.72

-1.71%↓

BIM

114.2

-1.13%↓

SRT3

228.6

+0.13%↑

GXI

56.7

+2.53%↑

ICAD

20.72

-1.71%↓

BIM

114.2

-1.13%↓

SRT3

228.6

+0.13%↑

GXI

56.7

+2.53%↑

ICAD

20.72

-1.71%↓

BIM

114.2

-1.13%↓

SRT3

228.6

+0.13%↑

GXI

56.7

+2.53%↑

ICAD

20.72

-1.71%↓

BIM

114.2

-1.13%↓

SRT3

228.6

+0.13%↑

GXI

56.7

+2.53%↑

ICAD

20.72

-1.71%↓

Kodu・Aktsiate loetelu・Nanobiotix

N
Nanobiotix

Avatud

2.71 -4.75

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

2.725

Max

2.905

Põhinäitajad
By Trading Economics
Sissetulek	-22M
Müük	9.3M
Kasumimarginaal	-235.461
Töötajad	108
EBITDA	-23M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+354.55% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	21. mai 2025

Turustatistika
By TradingEconomics
Turukapital	142M
Eelmine avamishind	7.46
Eelmine sulgemishind	2.71

Tehniline skoor

By Trading Central

Kindlus

Strong Bearish Evidence

2.83 / 2.995 Toetus ja vastupanu

Nanobiotix Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

27. apr 2025, 23:55 UTC

Market Talk

Oil Edges Higher Amid Hopes for Easing U.S.-China Trade Tensions -- Market Talk

27. apr 2025, 23:47 UTC

Market Talk

Gold Falls Amid Dollar Strength, Signs of Easing U.S.-China Trade Tensions -- Market Talk

27. apr 2025, 23:42 UTC

Market Talk

Nikkei May Rise as Fears About U.S.-China Tensions Ebb -- Market Talk

27. apr 2025, 23:12 UTC

Tulu

Sinopharm Group 1Q Rev CNY141.66B Vs. CNY147.27B >1099.HK

27. apr 2025, 23:12 UTC

Tulu

Sinopharm Group 1Q Net CNY1.46B Vs. Net CNY1.42B >1099.HK

27. apr 2025, 20:41 UTC

Tulu

Pharmaron Beijing 1Q Net CNY305.58M Vs. Net CNY230.56M >300759.SZ

27. apr 2025, 20:41 UTC

Tulu

Pharmaron Beijing: Higher Contributions From Laboratory Services Among Factors Supporting Results> 300759.SZ

27. apr 2025, 20:41 UTC

Tulu

Pharmaron Beijing 1Q Rev CNY3.10B Vs. CNY2.67B >300759.SZ

27. apr 2025, 18:41 UTC

Peamised uudised

Bessent Doesn't Know If Trump and Xi Have Talked on Trade -- Barrons.com

27. apr 2025, 11:00 UTC

Peamised uudised

Wall Street's New Tariff Safe Haven: High-Tax Biotech Stocks -- Heard on the Street -- WSJ

27. apr 2025, 05:41 UTC

Tulu

China Everbright Bank 1Q Net CNY12.46B Vs. Net CNY12.43B >601818.SH

27. apr 2025, 05:41 UTC

Tulu

China Everbright Bank: Lower Net Interest Income Weighed on Operating Income>601818.SH

27. apr 2025, 05:41 UTC

Tulu

China Everbright Bank 1Q Operating Income CNY33.10B Vs. CNY34.49B>601818.SH

27. apr 2025, 05:41 UTC

Tulu

China Everbright Bank 1Q Impairment Loss on Credit Assets Was CNY8.49B; Down 15.6% on Year>601818.SH

27. apr 2025, 05:41 UTC

Tulu

China Everbright Bank 1Q Operating Expenses Was CNY9.15B; Down 3.2%>601818.SH

27. apr 2025, 05:41 UTC

Tulu

China Everbright Bank 1Q Net Interst Income Was CNY22.54B; Down 6.8% on Year>601818.SH

27. apr 2025, 05:34 UTC

Tulu

Chongqing Rural Commercial Bank: 1Q Results Supported by Higher Net Interest Income>3618.HK

27. apr 2025, 05:34 UTC

Tulu

Chongqing Rural Commercial Bank 1Q Operating Income CNY7.22B Vs. CNY7.13B>3618.HK

27. apr 2025, 05:34 UTC

Tulu

Chongqing Rural Commercial Bank 1Q Net CNY3.75B Vs. Net CNY3.52B >3618.HK

27. apr 2025, 05:29 UTC

Tulu

China Shenhua Energy: Results Weighed by Fall in Selling Prices of Coal >1088.HK

27. apr 2025, 05:29 UTC

Tulu

China Shenhua Energy 1Q Net CNY13.37B Vs. Net CNY17.76B >1088.HK

27. apr 2025, 05:29 UTC

Tulu

China Shenhua Energy 1Q Rev CNY69.59B Vs. CNY87.65B >1088.HK

27. apr 2025, 05:29 UTC

Tulu

China Shenhua Energy: Lower Revenue From Electricity Sales Also Hurt Results >1088.HK

27. apr 2025, 05:21 UTC

Tulu

CMOC Group 1Q Net CNY3.95B Vs. Net CNY2.07B >3993.HK

27. apr 2025, 05:21 UTC

Tulu

CMOC Group: Cost Cuts Also Among Factors that Boosted 1Q Net >3993.HK

27. apr 2025, 05:21 UTC

Tulu

CMOC Group 1Q Rev CNY46.01B Vs. CNY46.12B >3993.HK

27. apr 2025, 05:21 UTC

Tulu

CMOC Group: Increase in Prices of Copper, Cobalt Supported Results>3993.HK

27. apr 2025, 03:00 UTC

Peamised uudised

Chinese Manufacturers Are Scouring the World for New Buyers -- WSJ

27. apr 2025, 00:30 UTC

Peamised uudised

Meta's 'Digital Companions' Will Talk Sex With Users -- Even Children -- WSJ

27. apr 2025, 00:30 UTC

Peamised uudised

Meta's 'Digital Companions' Will Talk Sex With Users -- Even Children -- WSJ -2-

Võrdlus sarnastega

Hinnamuutus

Nanobiotix Prognoos

Hinnasiht

By TipRanks

354.55% tõus

12 kuu keskmine prognoos

Keskmine 13 EUR 354.55%

Kõrge 16 EUR

Madal 10 EUR

Põhineb 2 Wall Streeti analüütiku instrumendi Nanobiotix 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

2 ratings

Osta

Hoia

Müü

Põhineb 2 analüütiku instrumendi Nanobiotix aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

2.83 / 2.995Toetus ja vastupanu

Recent bearish events outweigh bullish events.

All events are bearish.

There is one bearish event.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Nanobiotix

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.